Last Posted: Jul 30, 2020
- Consensus, Controversy, and Conversations About Gene Expression Profiling in Melanoma
WH Chan et al, JAMA Dermatology, July 29, 2020 - Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma A Systematic Review and Meta-analysis
MA Marchetti et al, JAMA Dermatology, July 29, 2020 - Prognostic Gene Expression Profiling in Cutaneous Melanoma Identifying the Knowledge Gaps and Assessing the Clinical Benefit
D Grossman et al, JAMA Dermatology, July 29, 2020 - Clinical implications of breast cancer tumor genomic testing.
Damodaran Senthil et al. The breast journal 2020 Jul - Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu Bin et al. JAMA dermatology 2020 Jul - Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
Chalmers Anna et al. The oncologist 2019 24(7) 963-972 - Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.
Chae Young Kwang et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 14(10) 1807-1817 - Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach.
Manca Antonella et al. Journal of translational medicine 2019 17(1) 289 - Polygenic risk score as a determinant of risk of non-melanoma skin cancer in a European-descent renal transplant cohort.
Stapleton Caragh P et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019 19(3) 801-810 - Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Seremet Teofila et al. Journal of translational medicine 2019 17(1) 303
.png)
No hay comentarios:
Publicar un comentario